Rigel Pharmaceuticals Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Rigel Pharmaceuticals stock.
View analyst ratings for Rigel Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Rigel Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Rigel Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Rigel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Rigel Pharmaceuticals.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) posted its quarterly earnings results on Tuesday, August, 3rd. The biotechnology company reported ($0.08) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.11) by $0.03. The biotechnology company earned $26.27 million during the quarter, compared to analyst estimates of $22.08 million. Rigel Pharmaceuticals had a negative net margin of 5.36% and a negative trailing twelve-month return on equity of 13.37%.
View Rigel Pharmaceuticals' earnings history.

Rigel Pharmaceuticals' stock was trading at $1.81 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RIGL stock has increased by 111.6% and is now trading at $3.83.
View which stocks have been most impacted by COVID-19.

3 brokerages have issued 12 month price targets for Rigel Pharmaceuticals' stock. Their forecasts range from $11.00 to $11.00. On average, they anticipate Rigel Pharmaceuticals' stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 187.2% from the stock's current price.
View analysts' price targets for Rigel Pharmaceuticals or view top-rated stocks among Wall Street analysts.

6 employees have rated Rigel Pharmaceuticals CEO Raul Rodriguez on Glassdoor.com. Raul Rodriguez has an approval rating of 84% among Rigel Pharmaceuticals' employees.

Some companies that are related to Rigel Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Novavax (NVAX), Incyte (INCY), Repligen (RGEN), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX) and Exelixis (EXEL).
View all of RIGL's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Aeterna Zentaris (AEZS), KushCo (KSHB), Novan (NOVN), Bionano Genomics (BNGO), OrganiGram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

Rigel Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (14.94%), BlackRock Inc. (9.81%), State Street Corp (6.26%), Vanguard Group Inc. (5.31%), Tamarack Advisers LP (3.75%) and Invesco Ltd. (3.02%).
View institutional ownership trends for Rigel Pharmaceuticals.

RIGL stock was sold by a variety of institutional investors in the last quarter, including Tamarack Advisers LP, State Street Corp, Dimensional Fund Advisors LP, BlackRock Inc., Panagora Asset Management Inc., Lord Abbett & CO. LLC, Rafferty Asset Management LLC, and Russell Investments Group Ltd..
View insider buying and selling activity for Rigel Pharmaceuticals or view top insider-selling stocks.

RIGL stock was purchased by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Millennium Management LLC, Nuveen Asset Management LLC, Schonfeld Strategic Advisors LLC, Wells Fargo & Company MN, Goldman Sachs Group Inc., CM Management LLC, and Simplex Trading LLC.
View insider buying and selling activity for Rigel Pharmaceuticals or or view top insider-buying stocks.

Shares of RIGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RIGL stock can currently be purchased for approximately $3.83.

Rigel Pharmaceuticals has a market capitalization of $654.36 million and generates $108.62 million in revenue each year. The biotechnology company earns $-29,740,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis.

Rigel Pharmaceuticals employs 169 workers across the globe.

Rigel Pharmaceuticals was founded in 1996.

The official website for Rigel Pharmaceuticals is www.rigel.com.

Rigel Pharmaceuticals is headquartered at 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080.

Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at (650) 624-1100 or via email at [email protected]